上気道感染症を科学する

出版社： 克誠堂出版
著者：
発行日： 2022-04-22
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784771905603
電子書籍版： 2022-04-22 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

いわゆる “かぜ”の疑問に答える1冊。患者から質問される、感染予防効果があるとされる食品について理論的背景を提示。呼吸器基礎疾患のある患者への対応も記載。

目次

  • 1．ウイルス別の伝播方法

    2．予防法、民間療法に裏付けはあるか？
    　　1）ワクチンによる予防法（COVID-19、インフルエンザ、RS）
    　　2）マスクと手洗い
    　　3）うがい、漢方
    　　4）ビタミンC、ビタミンD
    　　5）身体活動性、運動と免疫反応
    　　6）喫煙と睡眠
    　　7）食品
    　　　　a）プロバイオティクス、ヨーグルト
    　　　　b）チキンスープ、納豆、たまご酒
    　　　　c）ネギ、ハチミツ、ニンニク、ショウガ
    　　　　d）キャベツ、キュウリ、ブロッコリー、トマト

    3．治療と症状
    　　1）抗菌薬、二次感染のメカニズムと治療：
    　　　　特にA群溶連菌感染による咽頭扁桃炎の病態機序と抗菌薬治療について
    　　2）発熱
    　　3）咳嗽、喀痰
    　　4）筋肉痛
    　　5）総合感冒薬
    　　6）全身倦怠感

    4．喘息：悪化のメカニズムと対応

    5．COPD：悪化のメカニズムと対応

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 ウイルス別の伝播方法

P.10 掲載の参考文献
1) Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol 2021 ; 19 : 528-45.
 
2) Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020 ; 579 : 265-9.
 
3) 厚生労働省. 新型コロナウイルス感染症の国内発生動向 (令和3年10月19日時点) https://www.mhlw.go.jp/content/10906000/000846095.pdf
 
4) Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding. Lancet 2020 ; 395 : 565-74.
 
5) Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020 ; 117 : 7001-3.
PubMed
6) Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020 ; 26 : 681-7.
PubMed
7) Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 2020 ; 28 : 124-33.e4.
 
8) Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva : an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med 2020 ; 8 : 687-95.
PubMed
9) Deng W, Bao L, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nat Commun 2020 ; 11 : 4400.
PubMed
10) To KK, Tsang OT, Yip CC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020 ; 71 : 841-3.
PubMed
11) Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020 ; 582 : 557-60.
 
12) Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020 ; 581 : 465-9.
PubMed
13) Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020 ; 323 : 2249-51.
PubMed
14) Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 2020 ; 371 : m3862.
PubMed
15) van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020 ; 382 : 1564-7.
PubMed
16) Hirose R, Ikegaya H, Naito Y, et al. Survival of SARS-CoV-2 and influenza virus on the human skin : importance of hand hygiene in COVID-19. Clin Infect Dis 2020 ; ciaa1517.
 
17) Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020 ; 368 : eabb6936.
PubMed
18) Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2 : a review of viral, host, and environmental factors. Ann Intern Med 2021 ; 174 : 69-79.
PubMed
19) Choi H, Chatterjee P, Coppin JD, et al. Current understanding of the surface contamination and contact transmission of SARS-CoV-2 in healthcare settings. Environ Chem Lett 2021 ; 1-10.
 
20) Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 2010 ; 84 : 12658-64.
PubMed
21) Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005 ; 202 : 415-24.
PubMed
22) Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections : a living systematic review and meta-analysis. PLoS Med 2020 ; 17 : e1003346.
PubMed
23) 国立感染症研究所. 麻疹 2020年2月現在. IASR 2020 ; 41 : 53-5.
 
24) 田原舞乃, 竹田誠. 野生型麻疹ウイルスの二つのレセプター. ウイルス 2011 ; 61 : 249-56.
 
25) de Swart RL, Ludlow M, de Witte L, et al. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 2007 ; 3 : e178.
PubMed
26) Takeda M, Tahara M, Nagata N, et al. Wild-type measles virus is intrinsically dual-tropic. Front Microbiol 2012 ; 2 : 279.
PubMed
27) Shinya K, M Ebina, S Yamada, et al. Avian flu : influenza virus receptors in the human airway. Nature 2006 ; 440 : 435-6.
 
28) 新矢恭子. A型インフルエンザウイルスの宿主適応機序解明に関する研究. ウイルス 2008 ; 58 : 69-72.
 
29) Fukushima K, Takahashi T, Ito S, et al. Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3. Virology 2014 ; 464-465 : 424-31.
 
30) 加瀬哲男, 森川佐依子. 原因ウイルスとウイルス別の伝播方法. 日胸 2016 ; 75 : 946-56.
Medical*Online
31) Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020 ; 5 : 434-5
PubMed
32) Baggen J, Thibaut HJ, Strating JRPM, et al. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol 2018 ; 16 : 368-81.
PubMed
33) Jacobs SE, Lamson DM, St George K, et al. Human rhinoviruses. Clin Microbiol Rev 2013 ; 26 : 135-62.
PubMed
34) Stasiak AC, Stehle T. Human adenovirus binding to host cell receptors : a structural view. Med Microbiol Immunol 2020 ; 209 : 325-33.
PubMed
35) Anderson CS, Chu CY, Wang Q, et al. CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung. Pediatr Res 2020 ; 87 : 862-7.
PubMed
36) Chang A, Masante C, Buchholz UJ, et al. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol 2012 ; 86 : 3230-43.
PubMed
37) Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006 ; 66 : 193-292.
PubMed
38) 佐藤毅史, 荒瀬尚. 単純ヘルペスウイルスの新たな感染機構. 生化学 2009 ; 81 : 200-8.
 
39) Arii J, Goto H, Suenaga T, et al. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 2010 ; 467 : 859-62.
PubMed

2 予防法、民間療法に裏付けはあるか ?

P.19 掲載の参考文献
1) Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004 ; 5 : 987-95.
PubMed
2) Akkaya M, Kwak K, Pierce SK. B cell memory : building two walls of protection against pathogens. Nat Rev Immunol 2020 ; 20 : 229-38.
 
3) Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010 ; 363 : 2036-44.
PubMed
4) Stohr K, Kieny M, Wood D. Influenza pandemic vaccines : how to ensure a low-cost, low-dose option. Nat Rev Microbiol 2006 ; 4 : 565-6.
PubMed
5) Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol 2018 ; 16 : 47-60.
PubMed
6) Reber A, Chirkova T, Kim JH, et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 2012 ; 3 : 68-90.
PubMed
7) Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 2009 ; 3 : 37-49.
PubMed
8) Bell D, Nicoll A, Fukuda K, et al. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerging Infect Dis 2006 ; 12 : 81-7.
 
9) Stevenson E, Barrios L, Cordell R, et al. Pandemic influenza planning : addressing the needs of children. Am J Public Health 2009 ; 99 : S255-60.
PubMed
10) Nomura N, Matsuno K, Shingai M, et al. Updating the influenza virus library at Hokkaido University-It's potential for the use of pandemic vaccine strain candidates and diagnosis. Virology 2021 ; 557 : 55-61.
 
11) Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Disease. CDC Seasonal Flu Vaccine Effectiveness Studies. CDC website. URL : https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm (last reviewed Aug 26, 2021)
 
12) Barberis I, Myles P, Ault SK, et al. History and evolution of influenza control through vaccination : from the first monovalent vaccine to universal vaccines. J Prev Med Hyg 2016 ; 57 : E115-20.
PubMed
13) Nakayama T. An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. Vaccine 2016 ; 34 : 5815-8.
PubMed
14) Peck FB Jr. Purified influenza virus vaccine. A study of viral reactivity and antigenicity. JAMA 1968 ; 206 : 2277-82.
PubMed
15) Parkman PD, Hopps HE, Rastogi SC, et al. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977 ; 136 : S722-30.
PubMed
16) Gross PA, Ennis FA. Influenza vaccine : split-product versus whole-virus types-How do they differ. N Engl J Med 1977 ; 296 : 567-8.
PubMed
17) Gross PA, Ennis FA, Gaerlan PF, et al. Controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977 ; 136 : 623-32.
 
18) Sekiya T, Mifsud EJ, Ohno M, et al. Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza. Vaccine 2019 ; 37 : 2158-66.
PubMed
19) Shingai M, Nomura N, Sekiya T, et al. Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. Vaccine 2021 ; 39 : 3940-51.
PubMed
20) Sekiya T, Ohno M, Nomura N, et al. Selecting and using the appropriate influenza vaccine for each individual. Viruses 2021 ; 13 : 971.
PubMed
P.27 掲載の参考文献
1) 須原宏造, 宮崎泰成. 上気道感染症を科学する. 3. 民間療法, 予防方法に効果はあるか 1) マスクと手洗い. 日胸 2016 ; 75 : 984-7.
 
2) 新型インフルエンザ専門会議. 新型インフルエンザ流行時の日常生活におけるマスク使用の考え方. 厚生労働省ホームページ. URL : https://www.mhlw.go.jp/shingi/2008/09/dl/s0922-7b.pdf (accessed Aug 05 2021)
 
3) カケンテストセンター. バクテリア飛まつ捕集効率 (BFE) ・ウイルス飛まつ捕集効率 (VFE) 試験 (JIS T 9001・ASTM F 2101) | 一般財団法人カケンテストセンター. カケンテストセンターホームページ. URL : https://www.kaken.or.jp/test/search/detail/34 (accessed Aug 05 2021)
 
4) 日本衛生材料工業連合会, 全国マスク工業会. マスクのJISについて, 及び日衛連が計画するJIS適合性審査について「JIS T9001 医療用マスク, 一般用マスク」. 日本衛生材料工業連合会ホームページ https://www.jhpia.or.jp/about/jis/img/jis_works_t9001.pdf (accessed Aug 05 2021)
 
5) Asadi S, Cappa CD, Barreda S, et al. Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities. Sci Rep 2020 ; 10 : 15665.
PubMed
6) Davies A, Thompson KA, Giri K, et al. Testing the efficacy of homemade masks : would they protect in an influenza pandemic? Disaster Med Public Health Prep 2013 ; 7 : 413-8.
 
7) O'Kelly E, Pirog S, Ward J, et al. Ability of fabric face mask materials to filter ultrafine particles at coughing velocity. BMJ Open 2020 ; 10 : e039424.
PubMed
8) Heikkinen T, Jarvinen A. The common cold. Lancet 2003 ; 361 : 51-9.
PubMed
9) Cheng HY, Jian SW, Liu DP, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med 2020 ; 180 : 1156-63.
PubMed
10) Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2020 ; 11 : CD006207.
 
11) MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open 2015 ; 5 : e006577.
PubMed
12) Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission : a systematic review and meta-analysis. Travel Med Infect Dis 2020 ; 36 : 101751.
PubMed
13) Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19 : a systematic review and meta-analysis. Lancet 2020 ; 395 : 1973-87.
PubMed
14) Centers for Disease Control and Prevention. Interim guidance for the use of masks to control seasonal influenza virus transmission. CDC website. URL : https://www.cdc.gov/flu/professionals/infectioncontrol/maskguidance.htm (accessed Aug 23 2021)
 
15) WHO Guidelines. Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care. Geneva : World Health Organization, 2014.
 
16) Qualls N, Levitt A, Kanade N, et al. Community mitigation guidelines to prevent pandemic influenza-United States, 2017. MMWR Recomm Rep 2017 ; 66 : 1-34.
PubMed
17) Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 ; 382 : 1199-207.
PubMed
18) He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020 ; 26 : 672-5.
PubMed
19) Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic : a systematic review. Ann Intern Med 2021 ; 174 : 655-62.
PubMed
20) Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open 2021 ; 4 : e2035057.
PubMed
21) Greenhalgh T, Jimenez JL, Prather KA, et al. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet 2021 ; 397 : 1603-5.
PubMed
22) Brooks JT, Butler JC, Redfield RR. Universal masking to prevent SARS-CoV-2 transmission-the time is now. JAMA 2020 ; 324 : 635-7.
PubMed
23) Lyu W, Wehby GL. Community use of face masks and COVID-19 : evidence from a natural experiment of state mandates in the US. Health Aff (Millwood) 2020 ; 39 : 1419-25.
PubMed
24) World Health Organization. Mask use in the context of COVID-19 : interim guidance. World Health Organization website. URL : https://apps.who.int/iris/bitstream/handle/10665/337199/WHO-2019-nCov-IPC_Masks-2020.5-eng.pdf (accessed Aug 05 2021)
 
25) Brooks JT, Beezhold DH, Noti JD, et al. Maximizing fit for cloth and medical procedure masks to improve performance and reduce SARS-CoV-2 transmission and exposure, 2021. MMWR Morb Mortal Wkly Rep 2021 ; 70 : 254-7.
PubMed
26) Thomas Y, Boquete-Suter P, Koch D, et al. Survival of influenza virus on human fingers. Clin Microbiol Infect 2014 ; 20 : O58-64.
PubMed
27) L'Huillier AG, Tapparel C, Turin L, et al. Survival of rhinoviruses on human fingers. Clin Microbiol Infect 2015 ; 21 : 381-5.
PubMed
28) Kwok YLA, Gralton J, McLaws ML. Face touching : a frequent habit that has implications for hand hygiene. Am J Infect Control 2015 ; 43 : 112-4.
PubMed
29) 森功次, 林志直, 野口やよい, ほか. Norovirusの代替指標としてFeline Calicivirusを用いた手洗いによるウイルス除去効果の検討. 感染症誌 2006 ; 80 : 496-500.
 
30) Savolainen-Kopra C, Haapakoski J, Peltola PA, et al. Hand washing with soap and water together with behavioural recommendations prevents infections in common work environment : an open cluster-randomized trial. Trials 2012 ; 13 : 10.
PubMed
31) Azor-Martinez E, Yui-Hifume R, Munoz-Vico FJ, et al. Effectiveness of a hand hygiene program at child care centers : a cluster randomized trial. Pediatrics 2018 ; 142 : e20181245.
 
32) Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020 ; 323 : 1610-2.
PubMed
33) Yamagishi T, Ohnishi M, Matsunaga N, et al. Environmental sampling for severe acute respiratory syndrome coronavirus 2 during a COVID-19 outbreak on the Diamond Princess Cruise Ship. J Infect Dis 2020 ; 222 : 1098-102.
 
34) Singh D, Joshi K, Samuel A, et al. Alcohol-based hand sanitisers as first line of defence against SARS-CoV-2 : a review of biology, chemistry and formulations. Epidemiol Infect 2020 ; 148 : e229.
PubMed
35) Centers for Disease Control and Prevention. When and how to wash your hands. CDC website. URL : https://www.cdc.gov/handwashing/when-how-handwashing.html (accessed Aug 05 2021)
 
36) World Health Organization. Hand hygiene : why, how & when? World Health Organization website. URL : https://www.who.int/gpsc/5may/Hand_Hygiene_Why_How_and_When_Brochure.pdf (published 2009 ; accessed Aug 05 2021)
 
P.33 掲載の参考文献
1) UNICEF, WHO. Hand hygiene for all. UNICEF website. URL : https://www.unicef.org/reports/hand-hyginefor-all-2020 (publicated : June 2020)
 
2) Satomura K, Kitamura T, Kawamura T, et al. Prevention of upper respiratory tract infections by gargling : a randomized trial. Am J Prev Med 2005 ; 29 : 302-7.
PubMed
3) Pelletier JS, Tessema B, Frank S, et al. Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Ear Nose Throat J 2021 ; 100 : 192S-6S.
PubMed
4) Goodall EC, Granados AC, Luinstra K, et al. Vitamin D3 and gargling for the prevention of upper respiratory tract infections : a randomized controlled trial. BMC Infect Dis 2014 ; 14 : 273.
PubMed
5) Ide K, Yamada H, Matsuchita K, et al. Effects of green tea gargling on the prevention of influenza infection in high school students : a randomized controlled study. PLoS One 2014 ; 9 : e96373.
 
6) Yamada H, Takuma N, Daimon T, et al. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents : a prospective clinical study. J Altern Complement Med 2006 ; 12 : 669-72.
PubMed
7) Noda T, Ojima T, Hayasaka S, et al. Gargling for oral hygiene and the development of fever in childhood : a population study in Japan. J Epidemiol 2012 ; 22 : 45-9.
PubMed
8) Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2020 ; 11 : CD006207.
 
9) Stathis C, Victoria N, Loomis K, et al. Review of the use of nasal and oral antiseptic during a global pandemic. Future Microbiol 2021 ; 16 : 119-30.
PubMed
10) Singh S, Sharma N, Singh U, et al. Nasopharyngeal wash in preventing and treating upper respiratory tract infections : could it prevent COVID-19? Lung India 2020 ; 37 : 246-51.
 
11) Turner RB. The common cold. In : Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Philadelphia : Churchill Livingstone, 2009 : 809.
 
12) David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections : a systematic review and meta-analysis. Complement Ther Med 2019 ; 44 : 18-26.
PubMed
13) Yoshino T, Arita R, Horiba Y, et al. The use of maoto (Ma-Huang-Tang), a traditional Japanese Kanpo medicine, to alleviate flu symptoms : a systematic review and meta-analysis. BMC Complement Altern Med 2019 ; 19 : 68.
 
14) Kubo T, Nishimura H. Antipyretic effect to Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. Phytomedicine 2007 ; 14 : 96-101.
PubMed
15) Toriumi Y, Kamei T, Murata K, et al. Utility of Maoto in an influenza season where reduced effectiveness of oseltamivir was observed-a clinical, non-randomized study in children. Forsch Komplementmed 2012 ; 19 : 179-86.
 
16) Saito N, Kikuchi A, Yamaya M, et al. Kakkonto inhibits cytokine production induced by rhinovirus infection in primary cultures of human nasal epithelial cells. Front Pharmacol 2021 ; 12 : 687818.
PubMed
17) Kurokawa M, Tsurita M, Brown J, et al. Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice. Antiviral Res 2002 ; 56 : 183-8.
PubMed
18) Takayama S, Namiki T, Ito T, et al. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikkyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage : a structured summary of a study protocol for a randomized controlled trial. Trials 2020 ; 21 : 827.
 
19) Yamaya M, Sasaki T, Yasuda H, et al. Hochu-ekki-to inhibits rhinovirus infection in human tracheal epithelial cells. Br J Pharmacol 2007 ; 150 : 702-10.
PubMed
20) Nagai T, Nakao M, Shimizu Y, et al. Proteomic analysis of anti-inflammatory effects of a Kampo (Japanese herbal) medicine "Shoseiryuto (Xiao-Qing-Long-Tang)" on airway inflammation in a mouse model. Evid Based Complement Alternat Med 2011 ; 2011 : 604196.
 
P.41 掲載の参考文献
1) 石神昭人. ビタミンCの事典. 東京 : 東京堂出版, 2011.
 
2) Holford P, Carr AC, Jovic TH, et al. Vitamin C-an adjunctive therapy for respiratory infection, sepsis and COVID-19. Nutrients 2020 ; 12 : 3760.
PubMed
3) Meng L, Zhao X, Zhang H. HIPK1 interference attenuates inflammation and oxidative stress of acute lung injury via autophagy. Med Sci Monit 2019 ; 25 : 827-35.
 
4) Fisher BJ, Seropian IM, Kraskauskas D, et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med 2011 ; 39 : 1454-60.
PubMed
5) Colunga Biancatelli RML, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther 2020 ; 18 : 99-101.
PubMed
6) Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013 ; 2013 : CD000980.
PubMed
7) Sasazuki S, Sasaki S, Tsubono Y, et al. Effect of vitamin C on common cold : randomized controlled trial. Eur J Clin Nutr 2006 ; 60 : 9-17.
PubMed
8) Hemila H. Vitamin C and infections. Nutrients 2017 ; 9 : 339.
PubMed
9) Merchant AT, Curhan G, Bendich A, et al. Vitamin intake is not associated with community-acquired pneumonia in U.S. men. J Nutr 2004 ; 134 : 439-44.
PubMed
10) Hunt C, Chakravorty NK, Annan G, et al. The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections. Int J Vitam Nutr Res 1994 ; 64 : 212-9.
PubMed
11) Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a North American community hospital intensive care unit in May 2020 : a pilot study. Med Drug Discov 2020 ; 8 : 100064.
 
12) Zhang J, Rao X, Li Y, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care 2021 ; 11 : 5.
PubMed
13) Zhao B, Liu M, Liu P, et al. High dose intravenous vitamin C for preventing the disease aggravation of moderate COVID-19 pneumonia. A retrospective propensity matched before-after study. Front Pharmacol 2021 ; 12 : 638556.
PubMed
14) Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections : revised Ms SBMB 2020_166. J Steroid Biochem Mol Biol 2020 ; 202 : 105719.
PubMed
15) Moan J, Dahlback A, Ma L, et al. Influenza, solar radiation and vitamin D. Dermatoendocrinol 2009 ; 1 : 307-9.
PubMed
16) Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 2020 ; 12 : 988.
PubMed
17) Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections : a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol 2021 ; 9 : 276-92.
PubMed
18) Nanri A, Nakamoto K, Sakamoto N, et al. Association of serum 25-hydroxyvitamin D with influenza in case-control study nested in a cohort of Japanese employees. Clin Nutr 2017 ; 36 : 1288-93.
 
19) Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010 ; 91 : 1255-60.
PubMed
20) Urashima M, Mezawa H, Noya M, et al. Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic : a randomized controlled trial. Food Funct 2014 ; 5 : 2365-70.
PubMed
21) Arihiro S, Nakashima A, Matsuoka M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019 ; 25 : 1088-95.
PubMed
22) Shimizu Y, Ito Y, Yui K, et al. Intake of 25-hydroxyvitamin D3 reduces duration and severity of upper respiratory tract infection : a randomized, double-blind, placebo-controlled, parallel group comparison study. J Nutr Health Aging 2018 ; 22 : 491-500.
PubMed
23) Zhou YF, Luo BA, Qin LL. The association between vitamin D deficiency and community-acquired pneumonia : a meta-analysis of observational studies. Medicine (Baltimore) 2019 ; 98 : e17252.
PubMed
24) Rafiq R, Thijs W, Prein R, et al. Associations of serum 25 (OH) D concentrations with lung function, airway inflammation and common cold in the general population. Nutrients 2018 ; 10 : 35.
 
25) Khan S, Mai XM, Chen Y. Plasma 25-hydroxyvitamin D associated with pulmonary function in Canadian adults with excess adiposity. Am J Clin Nutr 2013 ; 98 : 174-9.
PubMed
26) Lautenbacher LA, Jariwala SP, Markowitz ME, et al. Vitamin D and pulmonary function in obese asthmatic children. Pediatr Pulmonol 2016 ; 51 : 1276-83.
PubMed
27) Kaufman HW, Niles JK, Kroll MH, et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One 2020 ; 15 : e0239252.
PubMed
28) Li Y, Tong CH, Bare LA, et al. Assessment of the association of vitamin D level with SARS-CoV-2 seropositivity among working-age adults. JAMA Netw Open 2021 ; 4 : e2111634.
 
29) Annweiler G, Corvaisier M, Gautier J, et al. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients : the GERIA-COVID Quasi-experimental study. Nutrients 2020 ; 12 : 3377.
 
30) Kuwabara A, Tsugawa N, Tanaka K, et al. Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D3. J Nutr Sci Vitaminol (Tokyo) 2009 ; 55 : 453-8.
PubMed
P.50 掲載の参考文献
1) 吉澤靖之. 3. 民間療法, 予防方法に効果はあるか 6) 運動と食品. 日胸 2016 ; 75 : 1006-11.
Medical*Online
2) Nieman DC, Pence BD. Exercise immunology : future directions. J Sport Health Sci 2020 ; 9 : 432-45.
PubMed
3) Nieman DC, Groen AJ, Pugachev A, et al. Detection of functional overreaching in endurance athletes using proteomics. Proteomes 2018 ; 6 : 33.
PubMed
4) Colbey C, Cox AJ, Pyne DB, et al. Upper respiratory symptoms, gut health and mucosal immunity in athletes. Sports Med 2018 ; 48 : 65-77.
PubMed
5) Nieman DC, Wentz LM. The compelling link between physical activity and the body's defense system. J Sport Health Sci 2019 ; 8 : 201-17.
 
6) Campbell JP, Turner JE. Debunking the myth of exercise-induced immune suppression : redefining the impact of exercise on immunological health across the lifespan. Front Immunol 2018 ; 9 : 648.
PubMed
7) Campbell JP, Turner JE. There is limited existing evidence to support the common assumption that strenuous endurance exercise bouts impair immune competency. Expert Rev Clin Immunol 2019 ; 15 : 105-9.
PubMed
8) Martin SA, Pence BD, Woods JA. Exercise and respiratory tract viral infections. Exerc Sport Sci Rev 2009 ; 37 : 157-64.
PubMed
9) Grande AJ, Keogh J, Silva V, et al. Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections. Cochrane Database Syst Rev 2020 ; 4 : CD010596.
PubMed
10) Nieman DC, Groen AJ, Pugachev A, et al. Proteomics-based detection of immune dysfunction in an elite adventure athlete trekking across the Antarctica. Proteomes 2020 ; 8 : 4.
 
11) Grande AJ, Reid H, Thomas EE, et al. Exercise prior to influenza vaccination for limiting influenza incidence and its related complications in adults. Cochrane Database Syst Rev 2016 ; 8 : CD011857.
PubMed
12) Mailing LJ, Allen JM, Buford TW, et al. Exercise and the gut microbiome : a review of the evidence, potential mechanisms, and implications for human health. Exerc Sport Sci Rev 2019 ; 47 : 75-85.
PubMed
13) Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 2011 ; 108 : 5354-9.
PubMed
14) Hagan T, Cortese M, Rouphael N, et al. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 2019 ; 178 : 1313-28.e13.
 
15) Ranasinghe C, Ozemek C, Arena R. Exercise and well-being during COVID 19-time to boost your immunity. Expert Rev Anti Infect Ther 2020 ; 18 : 1195-200.
PubMed
16) Simpson RJ, Katsanis E. The immunological case for staying active during the COVID-19 pandemic. Brain Behav Immun 2020 ; 87 : 6-7.
PubMed
17) Dwyer MJ, Pasini M, De Dominicis S, et al. Physical activity : benefits and challenges during the COVID-19 pandemic. Scand J Med Sci Sports 2020 ; 30 : 1291-4.
PubMed
18) Evangelista FS. Physical exercise and the renin angiotensin system : prospects in the COVID-19. Front Physiol 2020 ; 11 : 561403.
PubMed
P.54 掲載の参考文献
1) Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J Infect 2013 ; 67 : 169-84.
PubMed
2) Xie J, Zhong R, Wang W, et al. COVID-19 and smoking : what evidence needs our attention? Front Physiol 2021 ; 12 : 603850.
 
3) Groskreutz DJ, Monick MM, Babor EC, et al. Cigarette smoke alters respiratory syncytial virus-induced apoptosis and replication. Am J Respir Cell Mol Biol 2009 ; 41 : 189-98.
PubMed
4) Jaspers I, Horvath KM, Zhang W, et al. Reduced expression of IRF7 in nasal epithelial cells from smokers after infection with influenza. Am J Respir Cell Mol Biol 2010 ; 43 : 368-75.
PubMed
5) Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients : implications for COVID-19. Eur Respir J 2020 ; 55 : 2000688.
PubMed
6) Cohen S, Tyrrell DA, Russell MA, et al. Smoking, alcohol consumption, and susceptibility to the common cold. Am J Public Health 1993 ; 83 : 1277-83.
 
7) Lawrence H, Hunter A, Murray R, et al. Cigarette smoking and the occurrence of influenza : systematic review. J Infect 2019 ; 79 : 401-6.
PubMed
8) Jackson SE, Brown J, Shahab L, et al. COVID-19, smoking and inequalities : a study of 53 002 adults in the UK. Tob Control 2020 : tobaccocontrol-2020-055933.
PubMed
9) Simons D, Shahab L, Brown J, et al. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19 : a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 2021 ; 116 : 1319-68.
PubMed
10) Leung JM, Yang CX, Sin DD. Reply to : " Current smoking is not associated with COVID-19". Eur Respir J 2020 ; 55 : 2001340.
 
11) Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China : could nicotine be a therapeutic option? Intern Emerg Med 2020 ; 15 : 845-52.
PubMed
12) Haddad C, Bou Malhab S, Sacre H, et al. Smoking and COVID-19 : a scoping review. Tob Use Insights 2021 ; 14 : 1179173X21994612.
 
13) Grundy EJ, Suddek T, Filippidis F, et al. Smoking, SARS-CoV-2 and COVID-19 : a review of reviews considering implications for public health policy and practice. Tob Induc Dis 2020 ; 18 : 58.
 
14) Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 ; 382 : 1708-20.
 
15) Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020 ; 133 : 1032-8.
 
16) Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19 : a rapid systematic review and meta-analysis. PLoS One 2020 ; 15 : e0233147.
PubMed
17) Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med 2020 ; 75 : 107-8.
PubMed
18) Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study. BMJ 2020 ; 369 : m1966.
PubMed
19) Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19 : a systemic review and meta-analysis. J Med Virol 2020 ; 92 : 1915-21.
PubMed
20) Opp MR, Krueger JM. Sleep and immunity : a growing field with clinical impact. Brain Behav Immun 2015 ; 47 : 1-3.
PubMed
21) Oliveira de Almeida CM, Malheiro A. Sleep, immunity and shift workers : a review. Sleep Sci 2016 ; 9 : 164-8.
 
22) Giri A, Srinivasan A, Sundar IK. COVID-19 : sleep, circadian rhythms and immunity-repurposing drugs and chronotherapeutics for SARS-CoV-2. Front Neurosci 2021 ; 15 : 674204.
PubMed
23) Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002 ; 59 : 131-6.
PubMed
24) Tamakoshi A, Ohno Y. Self-reported sleep duration as a predictor of all-cause mortality : results from the JACC study, Japan. Sleep 2004 ; 27 : 51-4.
PubMed
25) Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's updated sleep duration recommendations : final report. Sleep Health 2015 ; 1 : 233-43.
 
26) Teodorescu MC, Teodorescu M. Tired and sick. Sleep 2012 ; 35 : 15-6.
PubMed
27) Fondell E, Axelsson J, Franck K, et al. Short natural sleep is associated with higher T cell and lower NK cell activities. Brain Behav Immun 2011 ; 25 : 1367-75.
PubMed
28) Spiegel K, Sheridan JF, Cauter EV. Effect of sleep deprivation on response to immunizaton. JAMA 2002 ; 288 : 1471-2.
 
29) Labrecque N, Cermakian N. Circadian clocks in the immune system. J Biol Rhythms 2015 ; 30 : 277-90.
PubMed
30) Kecklund G, Axelsson J. Health consequences of shift work and insufficient sleep. BMJ 2016 ; 355 : i5210.
PubMed
31) Cohen S, Doyle WJ, Alper CM, et al. Sleep habits and susceptibility to the common cold. Arch Intern Med 2009 ; 169 : 62-7.
 
32) Shibata M, Iwane T, Higuchi R, et al. Potential common factors associated with predisposition to common cold in middle-aged and elderly Japanese : a community-based cross-sectional study. Medicine (Baltimore) 2018 ; 97 : e10729.
PubMed
33) Prather AA, Janicki-Deverts D, Hall MH, et al. Behaviorally assessed sleep and susceptibility to the common cold. Sleep 2015 ; 38 : 1353-9.
 
34) Fatima Y, Bucks RS, Mamun AA, et al. Shift work is associated with increased risk of COVID-19 : findings from the UK Biobank cohort. J Sleep Res 2021 ; 30 : e13326.
PubMed
35) Rowlands AV, Gillies C, Chudasama Y, et al. Association of working shifts, inside and outside of healthcare, with severe COVID-19 : an observational study. BMC Public Health 2021 ; 21 : 773.
PubMed
P.59 掲載の参考文献
1) 加藤豪人. ヒトにおけるプロバイオティクスの有効性と腸内細菌叢との関わり. 腸内細菌誌 2019 ; 33 : 175-89.
Medical*Online
2) 雪印メグミルク. ヨーグルト研究室 : プロバイオティクスとは. 雪印メグミルクホームページ. URL : https://www.meg-snow.com/fun/academy/yogurt/probiotics/
 
3) 山城清二. 成人気道感染症の基本的考え方. 日内会誌 2009 ; 98 : 424-8.
 
4) 黒野祐一. 上気道感染症と粘膜免疫. 日耳鼻 2020 ; 123 : 1247-52.
 
5) Daniel N, Lecuyer E, Chassaing B. Host/microbiota interactions in health and diseases-Time for mucosal microbiology! Mucosal immunol 2021 ; 14 : 1006-16.
PubMed
6) 大島茂, 渡辺守. V. 腸内細菌 : 多彩な内科領域におけるトピックス. 腸管免疫と腸内細菌の密接な関わり合い. 日内会誌 2015 ; 104 : 81-5.
 
7) Darbandi A, Asadi A, Ghanavati R, et al. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19 : systemic review 2010-20. Int J Infect Dis 2021 ; 105 : 91-104.
 
8) Trivedi R, Barve K. Gut microbiome a promising target for management of respiratory diseases. Biochem J 2020 ; 477 : 2679-96.
PubMed
9) Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 2011 ; 108 : 5354-9.
PubMed
10) Wang J, Li F, Wei H, et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med 2014 ; 211 : 2397-410.
 
11) Szajewska H, Canani RB, Guarino A, et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr 2016 ; 62 : 495-506.
 
12) Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015 : CD006895.
PubMed
13) Zhang H, Yeh C, Jin Z, et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth Syst Biotechnol 2018 ; 3 : 113-20.
PubMed
14) Moreira-Rosario A, Marques C, Pinheiro H, et al. Gut microbiota diversity and C-reactive protein are predictors of disease severity in COVID-19 patients. Front Microbiol 2021 ; 12 : 705020.
 
P.63 掲載の参考文献
1) Jayawardena R, Sooriyaarachchi P, Chourdakis M, et al. Enhancing immunity in viral infections, with special emphasis on COVID-19 : a review. Diabetes Metab Syndr 2020 ; 14 : 367-82.
PubMed
2) Harrison SE, Oliver SJ, Kashi DS, et al. Influence of vitamin D supplementation by simulated sunlight or oral D3 on respiratory infection during military training. Med Sci Sports Exerc 2021 ; 53 : 1505-16.
PubMed
3) Rennard BO, Ertl RF, Gossman GL, et al. Chicken soup inhibits neutrophil chemotaxis in vitro. Chest 2000 ; 118 : 1150-7.
PubMed
4) Saketkhoo K, Januszkiewicz A, Sackner MA. Effects of drinking hot water, cold water, and chicken soup on nasal mucus velocity and nasal airflow resistance. Chest 1978 ; 74 : 408-10.
PubMed
5) Soda K, Kano Y, Sakuragi M, et al. Long-term oral polyamine intake increases blood polyamine concentrations. J Nutr Sci Vitaminol (Tokyo) 2009 ; 55 : 361-6.
PubMed
6) Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med 2016 ; 22 : 1428-38.
PubMed
7) Murakami K, Yamanaka N, Ohnishi K, et al. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct 2012 ; 3 : 674-8.
PubMed
8) Nagata C, Wada K, Tamura T, et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults : the Takayama study. Am J Clin Nutr 2017 ; 105 : 426-31.
PubMed
9) Katagiri R, Sawada N, Goto A, et al. Association of soy and fermented soy product intake with total and cause specific mortality : prospective cohort study. BMJ 2020 ; 368 : m34.
PubMed
10) Nozue M, Shimazu T, Charvat H, et al. Fermented soy products intake and risk of cardiovascular disease and total cancer incidence : the Japan Public Health Center-based Prospective study. Eur J Clin Nutr 2021 ; 75 : 954-68.
PubMed
11) Johnson BA, Hage A, Kalveram B, et al. Peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity. J Virol 2019 ; 93 : e01282-9.
PubMed
12) Yuan L, Zhang S, Wang Y, et al. Surfactin inhibits membrane fusion during invasion of epithelial cells by enveloped viruses. J Virol 2018 ; 92 : e00809-18.
PubMed
13) Oba M, Rongduo W, Saito A, et al. Natto extract, a Japanese fermented soybean food, directly inhibits viral infections including SARS-CoV-2 in vitro. Biochem Biophys Res Commun 2021 ; 570 : 21-5.
PubMed
14) Starosila D, Rybalko S, Varbanetz L, et al. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother 2017 ; 61 : e00539-17.
PubMed
15) Ibrahim HR, Higashiguchi S, Juneja LR, et al. A structural phase of heat-denatured lysozyme with novel antimicrobial action. J Agric Food Chem 1996 ; 44 : 1416-23.
 
16) Saito H, Sakakibara Y, Sakata A, et al. Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus. PLoS One 2019 ; 14 : e0217504.
PubMed
17) Fukai K, Inoue K, Takeuchi A, et al. New possibilities for egg white lysozyme : heat-denatured lysozyme partially inactivates select foot-and-mouth disease virus strains. Sci Rep 2021 ; 11 : 526.
PubMed
18) Takahashi H, Nakazawa M, Ohshima C, et al. Heat-denatured lysozyme inactivates murine norovirus as a surrogate human norovirus. Sci Rep 2015 ; 5 : 11819.
PubMed
19) Ouchi E, Niu K, Kobayashi Y, et al. Frequent alcohol drinking is associated with lower prevalence of self-reported common cold : a retrospective study. BMC Public Health 2012 ; 12 : 987.
PubMed
20) Messaoudi I, Asquith M, Engelmann F, et al. Moderate alcohol consumption enhances vaccine-induced responses in rhesus macaques. Vaccine 2013 ; 32 : 54-61.
PubMed
P.68 掲載の参考文献
1) Waris A, Macharia WM, Njeru EK, et al. Randomised double blind study to compare effectiveness of honey, salbutamol and placebo in treatment of cough in children with common cold. East Afr Med J 2014 ; 91 : 50-6.
 
2) Paul IM, Beiler J, McMonagle A, et al. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med 2007 ; 161 : 1140-6.
PubMed
3) Peixoto DM, Rizzo JA, Schor D, et al. Use of honey associated with Ananas comosus (Bromelin) in the treatment of acute irritative cough. Rev Paul Pediatr 2016 ; 34 : 412-7.
PubMed
4) Shadkam MN, Mozaffari-Khosravi H, Mozayan MR. A comparison of the effect of honey, dextromethorphan, and diphenhydramine on nightly cough and sleep quality in children and their parents. J Altern Complement Med 2010 ; 16 : 787-93.
PubMed
5) Ahmadi M, Moosavi SM, Zakeri S. Comparison of the effect of honey and diphenhydramine on cough alleviation in 2-5-year-old children with viral upper respiratory tract infection. J Gorgan Univ Med Sci 2013 ; 15 : 8-13.
 
6) Cohen HA, Rozen J, Kristal H, et al. Effect of honey on nocturnal cough and sleep quality : a double-blind, randomised, placebo-controlled study. Pediatrics 2012 ; 130 : 465-71.
PubMed
7) Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections : a systematic review and meta-analysis. BMJ Evid Based Med 2021 ; 26 : 57-64.
PubMed
8) Raeessi MA, Aslani J, Raeessi N, et al. Honey plus coffee versus systemic steroid in the treatment of persistent post-infectious cough : a randomised controlled trial. Prim Care Respir J 2013 ; 22 : 325-30.
PubMed
9) Pagano R, Negri E, Decarli A, et al. Coffee drinking and prevalence of bronchial asthma. Chest 1988 ; 94 : 386-9.
PubMed
10) Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. Cochrane Database Syst Rev 2014 ; 2014 : CD006206.
PubMed
11) Josling P. Preventing the common cold with a garlic supplement : a double-blind, placebo-controlled survey. Adv Ther 2001 ; 18 : 189-93.
PubMed
12) Kaji T, Hamada Y, Nakaya H, et al. Influence of ginger extract on body temperatures at high altitude. Jap J Mount Med 2014 ; 34 : 40-5.
 
P.71 掲載の参考文献
1) Kruchinina TV, Makhova AA, Shikh EV, et al. S-methylmethionin (vitamin U) : experimental studies and clinical perspective. Vopr Pitan 2018 ; 87 : 70-6.
PubMed
2) Mukherjee PK, Nema NK, Maity N, et al. Phytochemical and therapeutic potential of cucumber. Fitoterapia 2013 ; 84 : 227-36.
PubMed
3) Saeidi A, Soltani M, Daraei A, et al. The effects of aerobic-resistance training and broccoli supplementation on plasma dectin-1 and insulin resistance in males with type 2 diabetes. Nutrients 2021 ; 13 : 3144.
PubMed
4) Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007 ; 8 : 39-46.
 
5) Auinger A, Riede L, Bothe G, et al. Yeast (1,3) - (1,6) -beta-glucan helps to maintain the body's defence against pathogens : a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr 2013 ; 52 : 1913-8.
 
6) Passioti M, Maggina P, Megremis S, et al. The common cold : potential for future prevention or cure. Curr Allergy Asthma Rep 2014 ; 14 : 413.
PubMed
7) Kumar M, Tomar M, Bhuyan DJ, et al. Tomato (Solanum lycopersicum L.) seed : a review on bioactives and biomedical activities. Biomed Pharmacother 2021 ; 142 : 112018.
 
8) Ngwa W, Kumar R, Thompson D, et al. Potential of Flavonoid-Inspired Phytomedicines against COVID-19. Molecules 2020 ; 25 : 2707.
PubMed
9) Li N, Wu X, Zhuang W, et al. Tomato and lycopene and multiple health outcomes : umbrella review. Food Chem 2021 ; 343 : 128396.
 

3 治療と症状

P.87 掲載の参考文献
1) Sexton DJ, McClain MT. The common cold in adults : diagnosis and clinical features. UpToDate website. URL : https://www.uptodate.com/contents/the-common-cold-in-adults-diagnosis-and-clinical-features (last updated : May 24, 2021)
 
2) Alcaide ML. Bisno AL. Pharyngitis and epiglottitis. Infect Dis Clin North Am 2007 ; 21 : 449-69.
PubMed
3) Chow AW, Doron S. Evaluation of acute pharyngitis in adults. UpToDate website. URL : https://www.uptodate.com/contents/evaluation-of-acute-pharyngitis-in-adults (last updated : Sep 21, 2020)
 
4) Flores AR, Caserta MT. Pharyngitis. In : Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 9th ed. Philadelphia, Elsevier, 2020 : 824-31.
 
5) 西順一郎. 溶血性レンサ球菌感染症. 小児内科 2020 ; 52 : 819-24.
Medical*Online
6) 古川恵一. 劇症型溶連菌感染症. 日防菌防黴会誌 2018 ; 46 : 309-14.
 
7) Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000 ; 13 : 470-511.
PubMed
8) Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestation and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev 2014 ; 27 : 264-301.
PubMed
9) Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 2009 ; 11 : 1-12.
 
10) Georgalas CC, Tolley NS, Narula A. Tonsillitis. BMJ Clin Evid 2014 ; 2014 : 0503
 
11) Pichichero ME. Treatment and prevention of streptococcal pharyngitis in adults and children. UpToDate website. URL : https://www.uptodate.com/contents/treatment-and-prevention-of-streptococcal-pharyngitis-in-adults-and-children (last updated : Aug 24, 2021)
 
12) Brook I. Penicillin Failure in the treatment of streptococcal pharyngo-tonsillitis. Curr Infect Dis Rep 2013 ; 15 : 232-5.
PubMed
13) Brook I. Treatment challenges of group A beta-hemolytic streptococcal pharyngo-tonsillitis. Int Arch Otorhinolaryngol 2017 ; 21 : 286-96.
 
14) Casey JR, Pichichero ME. Metaanalysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2005 ; 24 : 909-17.
 
15) van Driel ML, De Sutter AI, Habraken H, et al. Different antibiotic treatments for group A streptococcal pharyngitis (Review). Cochrane Database Syst Rev 2016 (9) : 1-70.
 
16) Tesini BL, Caserta MT. Acute laryngitis. In : Mandell GL, Bennett JE, Dolin R, eds, Principles and Practice of Infectious Diseases, 9th ed. Philadelphia : Elsevier, 2020 : 832-4.
 
17) Nayak JL, Weinberg GA. Epiglottitis. In : Mandell GL, Bennett JE, Dolin R, eds, Principles and Practice of Infectious Diseases, 9th ed. Philadelphia : Elsevier, 2020 : 855-8.
 
18) DeMuri GP, Wald ER. Sinusitis. In : Mandell GL, Bennett JE, Dolin R, eds, Principles and Practic,e of Infectious Diseases, 9th ed. Philadelphia : Elsevier 2020 : 844-54.
 
P.90 掲載の参考文献
1) 岡林里枝, 川村孝. 上気道感染症を科学する. 2. 治療の裏付けはあるか 2) 解熱薬. 日胸 2016 ; 75 : 964-9.
 
2) 山城清二. 成人気道感染症診療の基本的考え方. 日内会誌 2009 ; 98 : 424-8.
 
3) Czubak J, Stolarczyk K, Orzel A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold : a systematic literature review. Adv Clin Exp Med 2021 ; 30 : 109-14.
PubMed
4) Little P, Moore M, Kelly J, et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care : pragmatic randomised factorial trial. BMJ 2013 ; 347 : f6041.
PubMed
5) Bachert C, Chuchalin AG, Eisebitt R, et al. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults : a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther 2005 ; 27 : 993-1003.
PubMed
6) Kim SY, Chang YJ, Cho HM, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev 2015 : CD006362.
PubMed
7) 小口敬伸, 笠井正志. 【あの疾患・治療はどうなった? 時を経て今どのような位置づけになったか, 専門家が解説! 】あの治療の現在の位置づけは? かぜ 総合感冒薬・鎮痛薬 (小児での使用). 治療 2010 ; 92 : 2751-5.
 
8) Graham NM, Burvell CJ, Douglas RM, et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990 ; 162 : 1277-82.
 
P.100 掲載の参考文献
1) 日本呼吸器学会 咳嗽・喀痰の診療ガイドライン2019作成委員会. 咳嗽・喀痰の診療ガイドライン 2019. 東京 : 日本呼吸器学会, 2019.
 
2) Irwin RS, French CL, Chang AB, et al. Classification of cough as a symptom in adults and management algorithms. CHEST Guideline and Expert Panel Report. Chest 2018 ; 153 : 196-209.
 
3) Lee KK, Davenport PW, Smith JA, et al. Global physiology and pathology of cough. Part 1 : cough phenomenology-CHEST Guideline and Expert Panel Report. Chest 2021 ; 159 : 282-93.
 
4) 塩谷隆信. 咳を聴きとり, 咳を止める. 咳の機序. 総合診療 2015 ; 25 : 427-31.
 
5) 塩谷隆信. 上気道感染症を科学する. 2. 治療の裏付けはあるか 3) 咳嗽, 喀痰. 日胸 2016 ; 75 : 970-7.
 
6) Widdicombe JG. Advances in understanding and treatment of cough. Monaldi Arch Chest Dis 1999 ; 54 : 275-9.
PubMed
7) Widdicombe J. Neuroregulation of cough : implication for drug therapy. Curr Opin Pharmacol 2002 ; 2 : 256-63.
PubMed
8) Keller JA, McGovern AE, Mazzone SB. Translating cough mechanisms into better cough suppressants. Chest 2017 ; 152 : 833-41.
PubMed
9) Mazzone SB, McGarvey L. Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough. Clin Pharmacol Ther 2021 ; 109 : 619-36.
PubMed
10) Falsey AR, Betts RF. The common cold. In : Niederman MS, ed. Respiratory infections in the elderly, 1st ed. New York : Raven Press, 1991 ; 73-85.
 
11) 石田直. 急性咳嗽・感染後咳嗽. 日胸 2015 ; 74 : 1189-99.
Medical*Online
12) Niimi A, Matsumoto H, Ueda T, et al. Impaired cough reflex in patients with recurrent pneumonia. Thorax 2003 ; 58 : 152-3.
PubMed
13) Morice AH, Kitt MM, Ford AP, et al. The effect of gefapixant, a P2X3 antagonist, on couth reflex sensitivity : a randomized placebo-controlled study. Eur Respir J 2019 ; 54 : 1900439.
 
14) Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough : a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 2020 ; 8 : 775-85.
PubMed
15) Caramia G, Gagliardini R, Ruffini E, et al. The management of cystic fibrosis with carbocysteine lysine salt : single-blind comparative study with ambroxol hydrochloride. J Int Med Res 1995 ; 23 : 284-93.
PubMed
16) Ishiura Y, Fujimura M, Yamamori C, et al. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol 2003 ; 55 : 504-10.
PubMed
17) Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration 1987 ; 51 (Suppl 1) : 37-41.
 
18) 宮本昭正, 井上洋西, 北村諭, ほか. TJ-19 ツムラ小青竜湯の気管支炎に対するPlacebo対照二重盲検群間比較試験. 臨医薬 2001 ; 17 : 1189-214.
Medical*Online
P.103 掲載の参考文献
1) Eccles R, Loose I, Jawad M, et al. Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med 2003 ; 4 : 118-24.
PubMed
2) Dupuis-Maguiraga L, Noret M, Brun S, et al. Chikungunyadisease : infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl Trop Dis 2012 ; 6 : e1446.
 
3) Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002 ; 112 Suppl 6 A : 4S-12S.
 
4) Xatzipsalti M, Kyarana S, Tsolia M, et al. Rhinovirus viremia in children with respiratory infections. Am J Respir Crit Care Med 2005 ; 172 : 1037-40.
 
5) Kessler HA, Trenholme GM, Vogelzang NJ, et al. Elevated creatine phosphokinase levels associated with influenza A/Texas/1/77 infection. Scand J Infect Dis 1983 ; 15 : 7-10.
PubMed
6) Bartley JM, Pan SJ, Keilich SR, et al. Aging augments the impact of influenza respiratory tract infection on mobility impairments, muscle-localized inflammation, and muscle atrophy. Aging (Albany NY) 2016 ; 8 : 620-35.
PubMed
7) Kucuk A, Cure MC, Cure E. Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis. Clin Rheumatol 2020 ; 39 : 2103-4.
 
8) Kim SY, Chang YJ, Cho HM, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev 2015 ; 9 : CD006362.
PubMed
P.108 掲載の参考文献
1) Malesker MA, Callahan-Lyon P, Ireland B, et al. Pharmacologic and nonpharmacologic treatment for acute cough associated with the common cold : CHEST Expert Panel Report. Chest 2017 ; 152 : 1021-37.
 
2) Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev 2014 ; 2014 : CD009281.
PubMed
3) 加地正郎, 柏木征三郎, 林田一男, ほか. 感冒剤PL顆粒および幼児用PL顆粒の普通感冒に対する薬効評価. 臨と研 1977 ; 54 : 205-13.
Medical*Online
P.111 掲載の参考文献
1) Ye C, Zhu W, Yu J, et al. Viral pathogens among elderly people with acute respiratory infections in Shanghai, China : preliminary results from a laboratory-based surveillance, 2012-2015. J Med Virol 2017 ; 89 : 1700-6.
 
2) Koren MA, Arnold JC, Fairchok MP, et al. Type-specific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers, 2009-2014. Influenza Other Respir Viruses 2016 ; 10 : 414-20.
PubMed
3) Smith AP. Twenty-five years of research on the behavioural malaise associated with influenza and the common cold. Psychoneuroendocrinology 2013 ; 38 : 744-51.
PubMed
4) da Rosa Mesquita R, Silva LCF Jr, Santana FMS, et al. Clinical manifestations of COVID-19 in the general population : systematic review. Wien Klin Wochenschr 2021 ; 133 : 377-82.
 
5) Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital : a cohort study. Lancet 2021 ; 397 : 220-32.
 
6) Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020 ; 15 : e0240784.
PubMed
7) Enoka RM, Duchateau J. Translating fatigue to human performance. Med Sci Sports Exerc 2016 ; 48 : 2228-38.
PubMed
8) Randall RE, Goodbourn S. Interferons and viruses : an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008 ; 89 : 1-47.
PubMed
9) Tian B, Yang J, Zhao Y, et al. Central role of the NF-κB pathway in the Scgb1a1-expressing epithelium in mediating respiratory syncytial virus-induced airway inflammation. J Virol 2018 ; 92 : e00441-18.
 
10) Yang X, Li F, Li Y, et al. Study on the correlation between NF-κB and central fatigue. J Mol Neurosci 2021 ; 71 : 1975-86.
 
11) Zhang XF, Tan CB, Yao ZX, et al. Adenovirus infection-associated central nervous system disease in children. Pediatr Infect Dis J 2021 ; 40 : 205-8.
PubMed
12) Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2021 ; 24 : 168-75.
PubMed
13) Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol : a prospective cohort study. Eur Respir J 2021 ; doi : 10.1183/13993003.01341-2021.
 

4 喘息 : 悪化のメカニズムと対応

P.119 掲載の参考文献
1) Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. J Virol 2010 ; 84 : 7418-26.
PubMed
2) Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008 ; 178 : 667-72.
PubMed
3) Rakes GP, Arruda E, Ingram JM, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999 ; 159 : 785-90.
PubMed
4) Gill MA, Bajwa G, George TA, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010 ; 184 : 5999-6006.
PubMed
5) Durrani SR, Montville DJ, Pratt AS, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012 ; 130 : 489-95.
 
6) Caliskan M, Bochkov YA, Kreiner-Moller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med 2013 ; 368 : 1398-407.
PubMed
7) Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005 ; 201 : 937-47.
PubMed
8) Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nat Med 2006 ; 12 : 1023-6.
 
9) Bochkov YA, Hanson KM, Keles S, et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol 2010 ; 3 : 69-80.
PubMed
10) Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 2012 ; 129 : 1506-14.
 
11) Zambrano JC, Carper HT, Rakes GP, et al. Experimental rhinovirus challenges in adults with mild asthma : response to infection in relation to IgE. J Allergy Clin Immunol 2003 ; 111 : 1008-16.
 
12) Kantor DB, Stenquist N, McDonald MC, et al. Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol 2016 ; 138 : 1467-71.
 
13) Bizzintino J, Lee WM, Laing IA, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2011 ; 37 : 1037-42.
PubMed
14) Lee WM, Lemanske RF Jr, Evans MD, et al. Human rhinovirus species and season of infection determine illness severity. Am J Respir Crit Care Med 2012 ; 186 : 886-91.
PubMed
15) Ashraf S, Brockman-Schneider R, Bochkov YA, et al. Biological characteristics and propagation of human rhinovirus-C in differentiated sinus epithelial cells. Virology 2013 ; 436 : 143-9.
PubMed
16) Nakagome K, Bochkov YA, Ashraf S, et al. Effects of rhinovirus species on viral replication and cytokine production. J Allergy Clin Immunol 2014 ; 134 : 332-41.
PubMed
17) Bonnelykke K, Sleiman P, Nielsen K, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet 2014 ; 46 : 51-5.
 
18) Bochkov YA, Watters K, Ashraf S, et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc Natl Acad Sci U S A 2015 ; 112 : 5485-90.
PubMed
19) Falsey AR, Hennessey PA, Formica MA,et.al.Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 ; 352 : 1749-59.
PubMed
20) Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bron chiolitis in the first year of life. Thorax 2010 ; 65 : 1045-52.
 
21) Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999 ; 354 : 541-5.
PubMed
22) Simoes EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010 ; 126 : 256-62.
 
23) Patel DA, You Y, Huang G, et a.Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma. J Allergy Clin Immunol 2014 ; 134 : 1402-12.e7.
 
24) Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007 ; 28 : 171-81.
PubMed
25) Kato M, Tsukagoshi H, Yoshizumi M, et al. Different cytokine profile and eosinophil activation are involved in rhinovirus- and RS virus-induced acute exacerbation of childhood wheezing. Pediatr Allergy Immunol 2011 ; 22 : e87-94.
PubMed
26) Rothenberg ME. Eosinophilia. N Engl J Med 1998 ; 338 : 1592-600.
PubMed
27) Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Eng J Med 1990 ; 323 : 1033-9.
 
28) Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts : a randomised controlled trial. Lancet 2002 ; 360 : 1715-21.
 
29) Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017 ; 195 : 302-13.
PubMed
30) Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden : a UK cohort study. Lancet Respir Med 2015 ; 3 : 849-58.
PubMed
31) Soma T, Iemura H, Naito E, et al. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. Allergol Int 2018 ; 67S : S3-S11.
PubMed
32) Gleich GJ, Flavahan NA, Fujisawa T, et al. The eosinophil as a mediator of damage to respiratory epithelium : a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988 ; 81 : 776-81.
 
33) Drake MG, Bivins-Smith ER, Proskocil BJ, et al. Human and mouse eosinophils have antiviral activity against parainfluenza virus. Am J Respir Cell Mol Biol 2016 ; 55 : 387-94.
PubMed
34) Domachowske JB, Dyer KD, Bonville CA, et al. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998 ; 177 : 1458-64.
PubMed
35) Bjerregaard A, Laing IA, Backer V, et al. High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations : a prospective cohort study. Clin Exp Allergy 2017 ; 47 : 1007-13.
PubMed
36) Mathur SK, Fichtinger PS, Kelly JT, et al. Interaction between allergy and innate immunity : model for eosinophil regulation of epithelial cell interferon expression. Ann Allergy Asthma Immunol 2013 ; 111 : 25-31.
PubMed
37) Nakagome K, Nagata M. Involvement and possible role of eosinophils in asthma exacerbation. Front Immunol 2018 ; 9 : 2220.
PubMed
38) Nagata M, Sedgwick JB, Bates ME, et al. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol 1995 ; 155 : 2194-202.
PubMed
39) Nagata M, Sedgwick JB, Kita H, et al. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 1998 ; 19 : 158-66.
 
40) Nakagome K, Shimizu T, Bochkov YA, et al. Cadherin-related family member 3 upregulates the effector functions of eosinophils. Allergy 2020 ; 75 : 1805-9.
PubMed
41) Wark PA, Bucchieri F, Johnston SL, et al. IFN-γ-induced protein 10 is novel biomarker of rhinovirus induced asthma exacerbation. J Allergy Clin Immunol 2007 ; 120 : 586-93.
 
42) Takaku Y, Nakagome K, Kobayashi T, et al. IFN-γ-inducible protein of 10 kDa upregulates the effector functions of eosinophils through β2 integrin and CXCR3. Respir Res 2011 ; 12 : 138.
 
43) Noguchi T, Nakagome K, Kobayashi T, et al. Effect of LTRA on IP-10-induced eosinophil adhesion to ICAM-1. Allergol Int 2016 ; 65 : S62-4.
PubMed
44) Djukanovic R, Harrison T, Johnston SL, et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014 ; 190 : 145-54.
 
45) Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015 ; 136 : 1476-85.
PubMed
46) Noguchi T, Nakagome K, Kobayashi T, et al. Effect of beta2-adrenergic agonists on eosinophil adhesion, superoxide anion generation, and degranulation. Allergol Int 2015 ; 64 : S46-53.
PubMed
47) Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005 ; 24 : 225-32.
PubMed
48) Ong BA, Forester J, Fallot A. Does influenza vaccination improve pediatric asthma outcomes? J Asthma 2009 ; 46 : 477-80.
PubMed

5 COPD : 悪化のメカニズムと対応

P.125 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン第5版作成委員会, 編. COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン 2018, 第5版. 東京 : 日本呼吸器学会, 2018.
 
2) Sapey E, Stockley RA. COPD exacerbations. 2 : aetiology. Thorax 2006 ; 61 : 250-8.
PubMed
3) Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006 ; 173 : 1114-21.
PubMed
4) Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998 ; 157 : 1498-505.
PubMed
5) Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease : identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011 ; 184 : 662-71.
PubMed
6) Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008 ; 63 : 951-5.
PubMed
7) Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 ; 363 : 1128-38.
PubMed
8) Martinez CH, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res 2014 ; 15 : 62.
PubMed
9) Terada K, Muro S, Ohara T, et al. Abnormal swallowing reflex and COPD exacerbations. Chest 2010 ; 137 : 326-32.
PubMed
10) Nagami S, Oku Y, Yagi N, et al. Breathing-swallowing discoordination is associated with frequent exacerbations of COPD. BMJ Open Respir Res 2017 ; 4 : e000202.
PubMed
11) Tanimura K, Sato S, Sato A, et al. Low serum free light chain is associated with risk of COPD exacerbation. ERJ Open Res 2020 ; 6 : 00288-2019.
PubMed
12) Hurst JR, Donaldson GC, Wilkinson TMA, et al. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005 ; 26 : 846-52.
PubMed
13) Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 ; 164 : 1618-23.
PubMed
14) Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections : systematic review and meta-analysis of individual participant data. BMJ 2017 ; 356 : i6583.
PubMed
15) Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO) : a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2015 ; 3 : 120-30.
PubMed
16) 加藤康幸, 研究代表. 新型コロナウイルス感染症 (COVID-19) 診療の手引き, 第6.0版. 厚生労働省ホームページ. https://www.mhlw.go.jp/content/000851077.pdf
 
17) Jacobs M, Van Eeckhoutte HP, Wijnant SRA, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur Respir J 2020 ; 56 : 2002378.
PubMed
18) Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan : the Nippon COPD Epidemiology study. Respirology 2004 ; 9 : 458-65.
PubMed

書評

最近チェックした商品履歴

Loading...